Current indications for Helicobacter pylori eradication therapy

Scandinavian Journal of Gastroenterology, Supplement

Volumn 31, Issue 215, 1996, Pages 70-73

  Tytgat, G N J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Clinical outcome; Cure; Current indications; Equivocal; Eradication therapy; Experimental; Helicobacter pylori positive; Reinfection

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISMUTH;

CONFERENCE PAPER; ERADICATION THERAPY; GASTRITIS; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; REINFECTION; DRUG COMBINATION; DUODENUM ULCER; DYSPEPSIA; HELICOBACTER INFECTION; MICROBIOLOGY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; REVIEW; STOMACH TUMOR; STOMACH ULCER;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 0029915848     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609094540     Document Type: Conference Paper

References (23)

1. Lee A. Peptic ulceration. H. pylori-induced ulcerogenesis - look to the host. Lancet 1993;341:280-1.
2. Xiang Z, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995;63:94-8.
3. Covacci A, Censini B, Bugnoli M, Petracca K, Burroni D, Macchia G, et al. Molecular characterisation of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993;90:5791-5.
4. Boren T, Falk P, Roth HA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993;262:1892-5.
5. Crabtree JE, Farmery SM, Lindley IJD, Figura N, Peichl P, Tompkins DS. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994;47:945-50.
6. Crabtree JE, Wyatt JL, Sobala GM, Miller G, Tompkins DS, Primrose JN, et al. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut 1993;34:1339-43.
7. Hirai M, Azuma T, Ito S, Kato T, Kohli Y,Fujihi N. High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric carcinoma patients. Int J Cancer 1994;56:55-80.
8. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol 51. Some parasitic and bacterial infections. Lyon, 1994.
9. Wotherspoon AC, Doglioni C, Diso TC, Pan L, Moochini A, DeBoni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
10. Calvert R, Randerson J, Evans P, Cawkwell L, Lewis F, Dixon MF, et al. Genetic abnormalities during transition from Helicobacter pylori-associated gastritis to low-grade MALToma. Lancet 1995;345:26-7.
11. Parsonnet J, Hanson S, Rodriguez L, Gelb AB, Warnke EA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. New Engl J Med 1994;330:1267-71.
12. Stolte H, Eidt S. Healing gastric lymphoma by eradication of Helicobacter pylori. Lancet 1993;342:525.
13. Penston JG. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8:369-89.
14. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 1994;106:1174-83.
15. McCarthy C, Patchett S, Collins RM, Beattie S, Keane C, O'Morain C. Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci 1995;40:114-19.
16. Bayerdörffer E, Ritter MM, Hatz R, Brooks W, Stolte M. Ménétrier's disease and Helicobacter pylori. New Engl J Med 1993;329:60.
17. Yamada T, Ahnen D, Alpers DH, Greenberg HB, Gray L, Josalyn KB, et al. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
18. Tytgat GNJ, Dixon MF. Helicobacter pylori infection: role in peptic ulcer disease. In: Northfield TC, Mendall M, Goggin PM, editors. Helicobacter pylori infection - pathophysiology, epidemiology and management. London: Kluwer Academic Publishers, 1993:75-87.
19. Tytgat GNJ, Dixon MF. Role of Helicobacter pylori in the pathogenesis of peptic ulcer disease. Practical implications for the clinician. In: Hunt RH, editor. Acid pump inhibitors and acid-related disorders. Osaka: Adis International, 1994:79-97.
20. Laine L. The long-term management of patients with bleeding ulcers: Helicobacter pylori eradication instead of maintenance antisecretory therapy. Gastrointest Endosc 1995;41:77-9.
21. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin N Am 1993;22:89-104.
22. Solcia E, Villani L, Fiocca R, Luinetti O, Boldorini R, Trespi E, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994;29 Suppl 201:28-34.
23. Kuipers EJ, Klinkenberg-Knol EC, Havu N, Festen HPM, Lamers CBHW, Jansen JBMJ, et al. Helicobacter pylori and development of atrophic gastritis during omeprazole maintenance therapy. Dutch Society for Gastroenterology Spring Meeting, March 1995, Veldhoven, p. 111 (Abstract).